Ever have those sleepless nights of tossing and turning, and then have difficulty rolling out of the rack in the morning? Well, Arena Pharmaceuticals
With APD125, the study showed, there was a statistically significant improvement in a patient's ability to remain asleep during the night after falling asleep. Patients in the study reported no adverse reactions, and APD125 did not impair cognitive function the morning after.
This is a noteworthy accomplishment for Arena for two reasons. First, the market for sleep drugs is huge. Last year, Sanofi-Aventis
Another reason is because this step demonstrates Arena's progress in trying to bring new products to market. The company is in the red, with most of its revenue coming from collaboration agreements with companies including Merck
In May, Arena entered a sale-leaseback transaction with BioMed Realty Trust
For related Foolishness: